We are live on ! Find out more
CYTHW

Cyclo Therapeutics, Inc. Warrant
CYTHW

Delisted

CYTHW was delisted on the 25th of March, 2025.

Back to rankings

1 hedge funds and large institutions have $2.48K invested in Cyclo Therapeutics, Inc. Warrant in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% less capital invested

Capital invested by funds: $2.66K → $2.48K (-$175)

50% less funds holding

Funds holding: 2 → 1 (-1)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
1
Holders Change
-1
Holders Change %
-50%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$49
2
UBS Group
UBS Group
Switzerland
-$19
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
1
Citadel Advisors
Florida
$2.48K -$49 -200 -2%
UBS Group
2
UBS Group
Switzerland
– -$19 -81 Closed

CYTHW Hedge Fund Activity: Q2 2024 in Review

1 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Cyclo Therapeutics, Inc. Warrant (CYTHW) for Q2 2024, worth a combined $2.48K — down 6.6% from $2.66K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of CYTHW and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.

The largest seller was Citadel Advisors, cutting an estimated $49.

  • 1 institutional investor held Cyclo Therapeutics, Inc. Warrant (CYTHW) as of Q2 2024, down from 2 in Q1 2024.
  • Funds reported $2.48K of Cyclo Therapeutics, Inc. Warrant stock for Q2 2024, down 6.6% quarter-over-quarter.
  • 0 funds opened new Cyclo Therapeutics, Inc. Warrant positions in Q2 2024 and 1 closed out, a net change of -1 holder.
  • The largest Cyclo Therapeutics, Inc. Warrant seller in Q2 2024 was Citadel Advisors, an estimated $49 sold.

Based on aggregated 13F filings for Q2 2024.